For almost 20 years, Mr. Hawkins has held executive and management roles at the world’s leading healthcare companies. Specializing in the advancement of life-changing technologies, Mr. Hawkins joined Truvian Sciences as President and Chief Executive Officer in January 2018. Prior to Truvian, Mr. Hawkins was Vice President and General Manager of the Reproductive and Genetic Health Business at Illumina, Inc. Before Illumina, he served as Senior Vice President of Global Marketing and Program Management for GenMark Diagnostics. Previously, Mr. Hawkins held roles of increasing responsibility in business development for Hologic, Third Wave Technologies and Abbott Laboratories. Mr. Hawkins holds a B.A. in Chemistry with honors from Concordia University and an M.B.A. from Keller Graduate School of Management.

Ms. Atkinson has more than 20 years of experience in the healthcare and life sciences industries, where she continuously creates customer-focused teams that achieve and exceed global commercial and sales goals. Prior to joining Truvian, Ms. Atkinson served as Epic Sciences’ Chief Commercial Officer, where she identified new strategic business opportunities and deepened existing strategic partnerships. Prior to Epic, Ms. Atkinson was Vice President of Business Development and Strategic partnerships at Edico Genome. Previously, she held roles of increasing responsibility at Illumina, including as Commercial Director of Global Channel Partners and Director, Global Channel Partners, LATAM & Inside Sales, Demand Generation and Product Care Teams. Ms. Atkinson’s previous experience also includes leadership roles at Fisher Scientific, Thermo Fisher and Beckman Coulter. She holds a B.A in Broadcast Journalism and Public Speaking from the University of Houston.

Dr. Bowen joined Truvian after well over a decade at Illumina, where he held several roles of increasing responsibility. Most recently, Dr. Bowen served as the Senior Director of Scientific Research in the Department of Research and Technology Development at Illumina. In this role, he was foundationally involved in the development of the chemical patterning technology that enabled commercialization of the $1000 genome on the HiSeqX platform in 2014. He was also responsible for defining the infrastructure which resulted in a scalable, cost-disruptive method of manufacturing patterned flow cells, enabling the development of the NovaSeq Series in 2017. Dr. Bowen is a primary contributor of over 25 issued patents in addition to a healthy pipline currently within the application process. He holds a B.S. in Physics and Mathematics from the University of San Francisco as well as a M.S. in Applied Physics and a Ph.D. in Physical Chemistry, both from the University of California, San Diego.

Dr. Marrinucci is a life science entrepreneur with a passion for introducing diagnostic technologies with potential to transform human health. She co-founded Truvian in late 2015 and leads research, operations, program management and strategic partnerships for the company. Prior to founding Truvian, Dr. Marrinucci founded Epic Sciences in 2008 and was the company’s Chief Scientific Officer. During her tenure at Epic, Dr. Marrinucci developed a novel circulating tumor cell technology and helped grow the company, overseeing its diagnostic collaborations with pharmaceutical companies and developing its clinical laboratory and assay development operations.

Dr. Marrinucci has been named to MIT Technology Review’s 35 Innovators Under 35, Foreign Policy’s Top 100 Leading Global Thinkers, and PharmaVoice 100’s Top Entrepreneurs. She was also named a 2016 Life Science Catalyst Award winner, has authored dozens of peer reviewed publications and is an inventor on 12 patents. Dr. Marrinucci also serves as an Advisor for Lynx Biosciences, a cancer diagnostic company. She holds a B.S. in Chemistry from the University of Vermont and a Ph.D. in Chemical Biology from The Scripps Research Institute.

Mr. Tran brings Truvian extensive experience in the medical device and diagnostics space, where he specializes in quality management and regulatory compliance. Throughout his career, he has orchestrated a variety of successful regulatory submissions and audits with the FDA, Health Canada, European Commission and other quality governing bodies worldwide. At Truvian, he is instrumental in the company’s plans toward securing FDA 510(k) clearance. Mr. Tran’s career in quality assurance includes his role as Director of Quality at GenMark Diagnostics, a leading provider of automated, multiplex molecular diagnostic testing systems. He has also held engineering roles with Life Technologies, Flextronics Medical, and Abbott Laboratories, where he was recognized with a management award for his leadership in implementing a new quality system and ProChain Project Management approach. Mr. Tran holds a B.S. from the School of Health Sciences at Excelsior College.